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Abstract
Congenital myopathies are a group of genetic muscle disorders characterized clinically by hypotonia and weakness,
usually from birth, and a static or slowly progressive clinical course. Historically, congenital myopathies have been
classified on the basis of major morphological features seen on muscle biopsy. However, different genes have now
been identified as associated with the various phenotypic and histological expressions of these disorders, and in
recent years, because of their unexpectedly wide genetic and clinical heterogeneity, next-generation sequencing
has increasingly been used for their diagnosis. We reviewed clinical and genetic forms of congenital myopathy and
defined possible strategies to improve cost-effectiveness in histological and imaging diagnosis.
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Background
The term congenital myopathy refers to a group of clin-
ically, genetically and histologically heterogeneous dis-
eases that mainly affect muscle tissue. The presence of
particular histopathological alterations on muscle biopsy
distinguishes these conditions from other neuromuscular
disorders. Congenital myopathy is caused by genetically
determined defects in structural proteins of muscle and
classified on the basis of muscle biopsy findings [1]. The
onset generally occurs in the neonatal period. Although
the precise epidemiology of congenital myopathy is not
known, it has an estimated incidence of around 1:25,000,
and has been reported to account for 14% of all cases of
neonatal hypotonia [2]. Although the classification of
congenital myopathy is under constant review as more
genes are identified and associated with its various
phenotypic and histological expressions, for the moment
it continues to be based mainly on the features seen on
muscle biopsy. Accordingly, congenital myopathy can be
divided into the following five forms:
1. nemaline myopathy (subtypes: rod, core-rod, cap
and zebra body myopathy);
2. core myopathy (subtypes: central core and
multiminicore myopathy);
3. centronuclear myopathy (subtypes: myotubular
myopathy and autosomal centronuclear myopathy);
4. congenital fiber-type disproportion myopathy;
5. myosin storage myopathy
This paper describes the different congenital myopathy
disease types, focusing, in particular, on their diagnosis
through muscle biopsy, their muscle MRI features, and
the use of genetic testing based on cutting-edge gene
analysis technologies (next-generation sequencing,
NGS). Although adult-onset sporadic nemaline myop-
athy, spheroid body myopathy, sarcotubular myopathy
and reducing body myopathy were all initially regarded
as forms of congenital myopathy, they were recently ex-
cluded from the official classification [1] on the basis of
expert opinion, which deemed that they may be more
appropriately grouped with other neuromuscular disor-
ders. For example, spheroid body myopathy caused by
mutations in TRIM32 and sarcotubular myopathy caused
by mutations in MYOT may more correctly be grouped
with the limb-girdle muscular dystrophies.
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Clinical characteristics
Clinical phenotype, in isolation, remains an inadequate
basis for distinguishing between the different types of con-
genital myopathy, as it is often poorly specific, usually
consisting of hypotonia and weakness (present at birth or
appearing in infancy) and a static or slowly progressive
clinical course. The clinical spectrum is nevertheless rec-
ognized to range from severe neonatal forms with con-
genital arthrogryposis to mild childhood-onset forms with
non-progressive hyposthenia and low muscle tone [1, 3].
In neonatal and very early-onset cases, the symptoms are
generally more pronounced, and may consist of reduced
fetal movements and subsequent development of arthrogry-
posis and clubfoot. Severe muscle hypotonia is often
present at birth and in the early months of life (floppy baby
sign), together with a frog-like posture, difficulty sucking,
and respiratory insufficiency. Other typical symptoms in
the first year of life are congenital hip dysplasia and hypo-
mimia (myopathic facies). As the child grows, the muscle
hypotonia remains stable, while motor milestones are de-
layed; bone and joint deformities may appear, such as joint
contractures, lordosis, scoliosis or a rigid spine. A signifi-
cant loss of muscle mass with a low body weight and dif-
fuse muscle atrophy are other common features [4].
Patients with congenital myopathy typically show dys-
morphic facial features secondary to muscle weakness, as-
sociated with an arched palate, micrognathia and pectus
carinatum or excavatum, the latter resulting from chest
muscle hypotonia. Abnormal extrinsic eye movements with
eyelid ptosis and strabismus may develop later on. Ophthal-
moparesis is a frequent clinical feature in some forms.
Nemaline myopathy
Nemaline myopathy is characterized by the presence of
small rod-like inclusions in muscle fibers. Made up
mainly of alpha-actinin, actin and other Z-band fila-
ments, these inclusions are clearly visualized by Gomori
trichrome staining [5].
Nemaline myopathy has an incidence of 1:50,000 live
births, although it may be more common in certain popula-
tions (e.g. in Ashkenazi Jews, or in the Amish community).
The clinical spectrum of nemaline myopathy is quite
broad, ranging from mild to severe phenotypes [6].
Children affected by severe, neonatal-onset forms,
which account for around 16% of all cases, are hyposthe-
nic, hypotonic from birth, and have difficulty sucking
and swallowing. They may present arthrogryposis and
dilated cardiomyopathy. Respiratory failure or aspiration
pneumonia will often lead to death in the first weeks or
first months of life.
The most common form, however, is less severe, being
characterized by weakness of the limbs, trunk and facial
muscles, and by a stationary or slowly progressive dis-
ease course. Adaptation to extrauterine life is adequate,
but the acquisition of motor milestones is delayed.
Muscle hypotonia is always present during the first year
of life. Weakness of the head muscles is associated with
distinctive facial features (an elongated face, high-arched
palate and tented upper lip) and with dysarthria and dys-
phagia. Although children affected by this form of my-
opathy develop muscle contractures and high-arched
feet, most are able to walk. Respiratory involvement is
the main prognostic factor [7].
One specific subtype of nemaline myopathy is cap myop-
athy, a very rare congenital type. Only 20 patients have been
described since its first description in 1981 [8]: 13 with a
sporadic and seven with a familial form [9–13]. Cap myop-
athy has neonatal or childhood onset and its progression is
slow. Affected individuals present weakness and hypotrophy
of axial and proximal muscle groups, a long face with high-
arched palate, scoliosis and breathing difficulties.
Zebra body myopathy is a benign congenital myop-
athy, characterized by congenital hypotonia and weak-
ness. Its prevalence is unknown; fewer than ten patients
have been described so far. Muscle biopsy shows zebra
bodies and other myopathic changes.
Core myopathy
The term core myopathy refers to forms of congenital
myopathy characterized histologically by the presence, in
muscle cells, of rounded structures called “cores” in
which oxidative activity ranges from markedly reduced
to absent, unlike the surrounding area where it is nor-
mal. On the basis of differences between these struc-
tures, as seen on biopsy, two separate entities have been
designated [14, 15]: central core myopathy is defined by
the presence of individual cores that are usually centrally
located, while multiminicore myopathy is morphologic-
ally characterized by the diffuse presence of numerous
small cores (multiminicores). The prevalence of these
forms is unknown.
The two core myopathy subtypes are the most com-
mon forms of congenital myopathy and clinically they
are highly heterogeneous. Central core myopathy is
inherited as an autosomal dominant or autosomal reces-
sive trait with variable penetrance [16]: its clinical sever-
ity can vary between members of the same family and
also with age. Autosomal recessive forms are clinically
more severe and there exist descriptions of patients with
fetal akinesia and congenital arthrogryposis [17]. With
the exception of these latter, neonatal-onset cases, core
myopathy has a fairly benign disease course. The symp-
toms include: delayed walking, occasional involvement
of the muscles of facial expression, reduced eye move-
ments, eyelid ptosis and hypotonia and weakness of the
proximal and axial muscles. Respiratory function is well
preserved. There have been rare reports of infants pre-
senting with a more serious clinical picture, including
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early respiratory failure [18]. Finally, some patients may
show only susceptibility to malignant hyperthermia and
raised serum creatine kinase (CK) levels.
The clinical characteristics of multiminicore myopathy,
too, can vary greatly, and they are, in part, genetically de-
termined [19]. Onset is usually in childhood or the late
teens but adult forms also exist. Four phenotypic forms
have been described, albeit with considerable overlap of
symptoms between them [20]. Patients with the most com-
mon phenotype (classic form) present severe axial muscle
weakness with scoliosis or stiffness of the spine, torticollis
and respiratory involvement. However, the degree of
muscle weakness is not always correlated with the severity
of the respiratory insufficiency. The progression of the
symptoms is slow and these patients may present a clinical
overlap with rigid spine congenital muscular dystrophy. In
a second group of patients, complete or partial external
ophthalmoplegia is present in addition to the muscle in-
volvement [21]. A third, small, group of patients presents
proximal weakness, typically of the pelvis or shoulder gir-
dle, associated with arthrogryposis. Finally, some cases with
a severe neonatal presentation have been described in the
literature [22]. In all these forms of multiminicore myop-
athy, the clinical manifestations usually have early onset
and CK levels are normal or only slightly raised. Some pa-
tients may experience muscle pain on exertion.
Centronuclear myopathy
The key characterizing feature of the forms collectively
referred to as centronuclear myopathy is the abnormal
position of the nuclei within muscle cells, i.e. they are
often exactly in the center of the cells. Furthermore, they
are larger than normal and have a vesicular appearance,
making them reminiscent of myotubes; hence the origin
of the term myotubular myopathy, which is the name of
one of the subtypes [23].
The term myotubular myopathy refers only to the X-
linked form of the condition (XLMTM), while the term
centronuclear myopathy is normally used to indicate the
autosomal form, inherited as a dominant or, more rarely,
recessive trait [24]. According to the findings of a recent
review of Italian patients [25], around 30% of centronuc-
lear myopathy cases remain genetically undiagnosed,
which suggests that there are still new disease-causing
genes to be identified.
Myotubular myopathy
The X-linked form of centronuclear myopathy has an esti-
mated incidence of around 2:100,000 male births [26, 27].
The first symptoms may even appear in the womb, consist-
ing of polyhydramnios and reduced fetal movements.
Affected subjects, usually boys, present at birth with hypo-
tonia and respiratory insufficiency. They can also have mul-
tiple arthrogryposis with spinal and rib cage deformities.
Dysphagia is a major problem and a nasogastric tube is
often needed for feeding. Reduced eye movements and eye-
lid ptosis are common features. Patients are often macroso-
mic and may have other malformations such as pyloric
stenosis, inguinal hernias and cryptorchidism. They gener-
ally die during the first year of life due to respiratory insuffi-
ciency or aspiration pneumonia. Only a small percentage of
affected subjects reach adolescence or adulthood, and these
cases require assisted mechanical ventilation and gastros-
tomy for feeding [28].
Exploration of the medical history may disclose a history
of repeated miscarriages of male fetuses on the mother’s
side of the family. There are no reports of cardiomyop-
athy, cardiac conduction defects or arrhythmias [29].
Female carriers are generally asymptomatic or may oc-
casionally show, in childhood, mildly progressive limb-
girdle weakness and hypomimia [30]. The presence of
muscle symptoms in female carriers seems to be linked
to an X chromosome inactivation defect [31, 32].
Autosomal centronuclear myopathy
Compared with the X-liked form, autosomal centronuc-
lear myopathy shows a greater genetic heterogeneity and
a later onset, i.e. in childhood or early adulthood. Cases
with onset in childhood present with hypotonia, distal/
proximal muscle weakness, rib cage deformities (some-
times associated with respiratory insufficiency), ptosis,
ophthalmoparesis and weakness of the muscles of facial
expression with dysmorphic facial features; the motor
milestones are reached, but delayed.
The adult form presents with moderate proximal
muscle weakness, which never becomes severe; the dis-
ease progresses slowly and affected individuals seem to
have a normal life expectancy, although loss of ambula-
tion is possible after 50 years of age.
Serum CK is normal or only mildly elevated, while
electromyography (EMG) shows non-specific myopathic
abnormalities.
Congenital fiber-type disproportion myopathy (CFTD)
In CFTD, the main histological abnormality (from which
the condition gets its name) is a disproportionate differ-
ence in fiber caliber between the type 1 (slow) and type
2 (fast) fibers, with the type 1 fibers found to be signifi-
cantly and consistently smaller than the type 2 ones. The
prevalence of CFTD is unknown. Most affected children
present with hypotonia and mild-to-severe generalized
muscle weakness at birth or within the first year of life.
Motor milestones are delayed, head control is poor, and
the muscle weakness is particularly evident facially and
at the pelvis and shoulder girdle. Deep tendon reflexes
are reduced or absent. In more than 90% of affected in-
dividuals, the muscle weakness is static but the overall
disease course is slowly progressive [33].
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At least 30% of those affected by CFTD present signifi-
cant respiratory muscle hypotonia, which leads to de-
fective functioning of the chest bellows. The disease can
occur at any age; some children are affected by CFTD
from infancy, and these cases show severe respiratory in-
volvement, but this does not necessarily mean a poor
prognosis. Some patients, on the other hand, develop
mild respiratory failure which causes nocturnal hypoxia
and hypercapnia resulting in symptoms such as morning
headaches, daytime fatigue, decreased appetite, weight
loss, difficulty sleeping and frequent lung infections.
Dysphagia is present in 30% of children with CFTD.
Chewing and swallowing difficulties can cause ingestion
of food, liquid, saliva or other material into the lungs
and lead to aspiration pneumonia. As in other forms of
congenital myopathy, dental crowding and a high arched
palate are typical features. Infants with severe bulbar
weakness may have feeding problems that, if they persist
beyond the first months of life, require intervention (en-
teral feeding and/or gastrostomy). The mildest feeding
problems often subside over time.
Contractures may be present at birth or occur in older
children as a result of decreased mobility due to muscle
hypotonia. Contractures of the ankles, fingers, hips, el-
bows and knees occur in about 25% of affected children.
Congenital hip dislocation and clubfoot may also be
present. Hypotonia and hypotrophy of the paraspinal
muscles causes rotation of the vertebral bodies resulting
in scoliosis, kyphoscoliosis and lordosis in 25% of cases,
or more. Contractures and abnormalities of the spine
are not necessarily associated with greater disease
severity.
Myosin storage myopathy
This form, first reported in 1971 [34] and subsequently
termed myosin storage myopathy [35], is a rare condi-
tion associated with mutations in a myosin heavy chain
beta (MHC-β) isoform that is expressed primarily in the
heart, but also in type 1 skeletal muscle fibers. To date,
there exist descriptions of clinical phenotypes associated
with hypertrophic or dilated cardiomyopathy and also
with a wide range of skeletal myopathies including distal
myopathy [36], myosin storage myopathy itself [35],
CFTD [37] and a form of multiminicore myopathy [38].
Cardiac involvement usually occurs in isolation, but can
also appear in association with other forms of congenital
myopathy [39]. The clinical manifestations are highly
variable even within single families. Onset usually occurs
in childhood, with delayed motor milestones. Calf
pseudo-hypertrophy and foot drop are common features.
Lack of strength in the wrists and hands is a major fea-
ture of Laing distal myopathy, but it can also manifest it-
self, more subtly, in the various forms of congenital
myopathy. The clinical course is slowly progressive and
over time patients may develop respiratory insufficiency
secondary to the myopathy, and bone and joint deform-
ities such as scoliosis caused by reduced axial muscle
strength. Recently a cohort of 21 Italian patients showed
a wide spectrum of clinical presentations, including dif-
ferent ages at onset and different patterns of muscle
weakness and cardiac involvement [40]. Considering this
“blurred clinical-genetic scenario”, the authors suggested
that there exist three forms of this type of myopathy: 1)
an early-onset distal myopathy with cores, 2) a late-
onset form of distal myopathy without histological
evidence of cores and with variable association of cardio-
myopathy and/or fiber-type disproportion, and 3) the
least frequent form consisting of limb-girdle involve-
ment with myofibrillar damage. They also underlined
that there is no correlation of mutation sites with sever-
ity and that the phenotype cannot be predicted on the
basis of the genotype [40, 41].
Diagnostic approaches
Congenital myopathy is usually suspected on the basis of
the clinical presentation, even though, as we have said,
this can be highly variable. Although, for this reason, it
is extremely difficult to make an accurate diagnosis, this
should nevertheless be attempted before running the
specific genetic tests that, it is hoped, will establish the
correct molecular diagnosis — a crucial objective from
the perspective of prognosis, prevention and treatment.
A correct diagnostic approach requires the integration
of data from: clinical evaluations (including a detailed
family history), muscle biopsy (including histological,
immunohistochemical and electron microscopy exami-
nations) and muscle MRI. Serum CK measurement and
EMG, which are very useful diagnostic tools in other
neuromuscular disorders, are not particularly helpful for
diagnosing congenital myopathy, given that CK levels
are usually normal or mildly elevated, while EMG can
either be normal or, at most, show myopathy-like find-
ings or neuropathic changes, as seen in some cases of
nemaline myopathy. Ultrasound images, on the other
hand, may be more suggestive, for example in some
cases of central core myopathy in which it is possible to
appreciate increases in fat or connective tissue; however,
even these findings have to be considered largely
nonspecific.
Given the complexity of the clinical evaluation of
these forms, a diagnostic algorithm is needed that
clearly sets out the importance and significance of the
various instrumental tests that should be used in
order to reach the most accurate diagnosis possible.
Today, thanks to the possibility of combining genetic
data (including the dataset obtained by massive ana-
lysis of multiple genes with methods of next-
generation sequencing, NGS) with clinical and
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morphological findings and MRI results, our chances of
achieving a precise diagnosis are increasing all the time
[42, 43]. Thus, we here summarize the three major steps,
namely histological, myoimaging and genetic, to follow in
order to achieve a complete diagnosis in the different
groups of congenital myopathies.
Histological findings in muscle biopsies
Figure 1 summarizes major histological findings in con-
genital myopathy. The histopathological features of the
main pathological categories are described below.
Nemaline bodies
The nemaline bodies (small rod-like inclusions in muscle
fibers) that characterize nemaline myopathy are typically
visualized by Gomori trichrome staining. Nemaline bod-
ies consist mainly of alpha-actinin, and on electron mi-
croscopy they are visible as rod-like or oval-shaped
electron-dense structures. They are usually located in
the cytoplasm and often cluster at the periphery of
muscle fibers; however, they can sometimes be present
in the nucleus, and in such cases they are very difficult
to identify. Nemaline bodies can also be difficult to
Fig. 1 Pathological features in skeletal muscle biopsy observed in congenital myopathies. a Nemaline rods. Gomori trichrome stain showing clusters
of purple staining rods at the periphery of most fibers and some internal within fibers. b Cores. Cytochrome c oxidase stain demonstrating numerous
cores of varying size, centrally or peripherally. c Central nuclei. Quadriceps biopsy from a boy presenting X-linked myotubular myopathy. Hematoxylin–
eosin stain (HE) showed large central nuclei in several fibers. d Central nuclei. Quadriceps biopsy from a 5-year-old patient with centronuclear
myopathy due to a mutation in DNM2. HE demonstrated centrally placed nuclei in the majority of fibers, variation in fiber size and increased
connective tissue. e Multi-minicores. NADH-TR stain showing areas in both fiber types of varying size and number devoid of oxidative enzyme stain. f
Congenital fiber type disproportion. ATPase pre-incubated at pH 9,6 stain showing the small size of the light-staining type 1 fibers and
type 1 fiber predominance
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identify in extremely young patients, under 12 months
of age, in whom the fibers are minute. The number of fi-
bers affected is variable, as is the number of bodies a
fiber contains, but these aspects are unrelated to the se-
verity of the phenotype. A wide variation in fiber size
may be observed, although type 1 fiber atrophy and type
1 fiber uniformity or predominance are common.
Nemaline bodies may occur in other severe forms of
muscle degeneration, both primary and secondary [44],
and in healthy muscle during the physiological aging
process.
Cap myopathy
In this particular form, the muscle fibers contain well
demarcated subsarcolemmal cap-like (triangular) inclu-
sions, which appear reddish or purple with the modified
Gomori trichrome stain and eosinophilic when stained
with hematoxylin and eosin; they show no ATPase activ-
ity [44]. Ultrastructural studies show that these caps are
present haphazardly on the myofilaments, that the ar-
rangement of the myofibrils in the affected zone does
not respect the orientation of the fibers, and that the
normal structure of the sarcomere is lacking. The Z-
bands are thickened. The structure of the adjacent sar-
comeres is normal. Between 4% and 100% of fibers are
affected and the proportion affected seems to show a
correlation with the severity of the disease and the pa-
tient’s age.
Zebra body myopathy
Zebra bodies are elongated filamentous structures with
thin, dark bans alternating with wider dark ones. Zebra
bodies may be a prominent feature of a biopsy and this
led to the designation of “zebra body myopathy” but they
can be also found in myotendinous junctions and nor-
mal extraocular muscle [44].
Core and minicores
The cores can be single or multiple and they are seen
mainly in type 1 fibers. As the disease evolves, there may
be more than one core per fiber, even though there are
rarely more than two or three. Under electron micros-
copy, core areas are characterized by the absence of both
mitochondria and glycogen, and by a variable degree of
destruction of the contractile apparatus; the cores appear
structured or unstructured, depending, respectively, on
whether or not sarcomeric organization is preserved.
Histochemical staining for ATPase activity does not de-
tect structured cores (which are the more frequent),
while unstructured ones show up as lighter areas com-
pared with normal fiber areas. Biopsy can show mild
variation in fiber diameter, but there are also reports of
muscle biopsies revealing not only cores, but also a
marked dystrophic pattern and fibrotic tissue replacing
muscle tissue [45]. Instead, in very early-onset cases, the
formation of the cores may not yet be visible, which
seems to suggest an age-dependent pathogenic mechan-
ism. This has been observed in a mouse model of the
disease [46].
Like cores, minicores can be detected using stains for
oxidative enzymes (NADH, COX and SDH); on cross
sections they often appear only as indistinct irregularities
in the texture of the muscle tissue or as punctiform
areas with no staining. Multiminicore myopathy is char-
acterized by hypotrophic fibers and type 1 fiber predom-
inance. Under electron microscopy, minicores present as
focal areas of myofibrillar disruption with absence of
mitochondria. Immunohistochemistry may reveal accu-
mulations of proteins such as desmin, myotilin and fila-
min C, both in central cores and in minicores, although
these findings are not indicative of a specific genetic
form [47]. Finally, it should be remembered that cores
and minicores may be a non-specific finding, given that
they can be observed in other conditions, such as de-
nervation, certain metabolic conditions, and even after
eccentric exercise in healthy subjects.
Centronuclear myopathy
The main histopathological feature of X-linked myotub-
ular myopathy is the presence of large central nuclei.
These, which can occur physiologically in muscle fi-
bers during the early stages of maturational develop-
ment, i.e. in embryonal myotubes (with the difference
that embryonal myotubes, unlike, mature muscle fi-
bers have yet to differentiate into type 1 and type 2
fibers), have a vesicular appearance and sometimes
occupy the whole of the fiber cytoplasm. A striking
feature associated with central nuclei is the presence
of dark-staining areas under oxidative enzyme stains
and PAS staining, reflecting aggregation of mitochon-
dria and glycogen. On staining for ATPases and oxi-
dative enzymes the nuclei appear as optically empty
vacuoles. Type 1 fibers may be predominant, and
most fibers, particularly the type 1 kind, are hypo-
trophic [44]. Symptomatic female carriers of myotub-
ular myopathy and benign, late-onset cases have been
reported to show characteristic histopathological
changes consisting of a reorganization of the myofi-
bers and myofibrillar pattern that results in the pres-
ence, detectable under NADH and PAS staining, of
dark cords lying just below the fiber perimeter; these
fibers have been called “necklace fibers” [27].
In autosomal centronuclear myopathy, the nuclei are
not large, but they are often surrounded by a clear halo,
where oxidative enzymatic activity is reduced; there can
be multiple internal nuclei in myofibers, a finding that
allows differential diagnosis versus other forms of
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myopathy without overt internal nuclei. All the alter-
ations described preferentially affect type 1 fibers which
appear smaller, but more numerous (type 1 fiber pre-
dominance). Type 2 fibers are usually hypertrophic. The
only other typical feature is the presence of “radial
strands”, which are probably the result of a disruption of
the myofibrillar network. These changes are clearly vis-
ible under NADH staining. It is interesting to observe
that there is a weak association between genotype and
histology, and we recently [25] underlined that radial
sarcoplasmic strands, previously described only in late-
onset cases, are actually a constant finding in patients
with centronuclear myopathy, even when onset occurs
in the neonatal period [25].
Congenital fiber-type disproportion (CFTD)
The original criteria for CFTD [44] stipulated that the
type 1 fibers should have a diameter at least 12% smaller
than the mean diameter of the type 2A and/or type 2B
fibers and that key pathological features of other forms
of congenital myopathy (e.g. rods, cores or central nu-
clei) should be absent. Fiber disproportion can indeed
occur in various other conditions, too, including nema-
line myopathy and centronuclear myopathy, and the sta-
tus of CFTD as a distinct nosological entity is therefore
still debated. Recent studies suggest that the diameter of
type 1 muscle fibers in individuals affected by CFTD is
between 40% and 80% smaller than that of type 2 fibers.
For this reason, a discrepancy of 35–40% has been sug-
gested as the best criterion for diagnosing CFTD [33].
CFTD is often associated with type 1 fiber predomin-
ance. Pathological findings on biopsy may change over
time, and in some individuals a diagnosis of CFTD re-
quires a second biopsy.
Magnetic resonance imaging
In recent years, the application of muscle MRI tech-
niques, also in patients with congenital myopathy, has
made a useful contribution to the differential diagnosis
of myopathic pictures with overlapping clinical-
pathological features [48]. Indeed, muscle MRI can be
used to identify, non-invasively, diffuse or localized ab-
normalities in individual muscle bellies, and thus to
identify any known disease patterns and their possible
correlations with genetically defined forms [49, 50]; the
method can also be used to study patterns of muscle in-
volvement linked to new genetic forms [51, 52]. The
high cost of muscle MRI may thus be justified by the
fact that its capacity to identify specific disease patterns
can open the way for more targeted biochemical and
genetic investigations, thereby reducing the use of more
expensive laboratory tests. Furthermore, unlike muscle
biopsy, this examination, being non-invasive, can be
repeated many times without causing patients excessive
discomfort.
The first MRI studies in sufficiently large congenital
myopathy case series date back to Jungbluth and col-
leagues’ description of patterns of muscle involvement in
central core and nemaline myopathy patients [48]. It has
since been shown that the pattern of muscle involve-
ment on MRI can be correlated more specifically with
the gene defect than with histopathological changes, and
the study of larger populations with specific genetic al-
terations (see details on genetic determinants below) has
made it possible to document more or less selective and
diagnostic patterns. In this regard, the pattern of abnor-
malities found on muscle MRI in patients with muta-
tions in RYR1 is the most characteristic: the gluteus
maximus is the most affected pelvic muscle, whereas in
the thigh, there is far greater involvement of the ad-
ductor magnus than of the adductor longus, of the vas-
tus lateralis than of the rectus femoris, and of the
sartorius than of the gracilis. In mild cases, the first
muscle involvement is thought to be that of the sartorius
and, to a lesser degree, the adductor magnus. More gen-
erally, the muscles of the posterior compartment of the
thigh are less affected than those of the anterior com-
partment. Although muscular degeneration is, overall,
less marked in the lower leg than in the thigh, the soleus
muscle is usually more affected than the gastrocnemius
lateralis, which in turn is more affected than the gastro-
cnemius medialis. In the anterior compartment, the
peroneal group is more affected than the tibialis anterior
group [53]. Differently from the above description, pa-
tients with mutations in SEPN1 show, at thigh level, se-
lective involvement of the sartorius, adductor and biceps
femoris muscles with relative sparing of the gracilis and
rectus femoris; the vastus lateralis, medialis and interme-
dius, and the semimembranosus and semitendinosus
muscles are less affected than other muscles. The muscle
most affected in the lower leg is the gastrocnemius,
while in the anterior compartment there is appreciable
involvement of the extensor muscles of the toes and the
peroneal muscles; the impairment of the tibialis anterior
and soleus muscles is less marked [49].
Even though, from a clinical perspective, nemaline my-
opathy is the congenital myopathy most frequently en-
countered in the general population there have been few
studies of genes linked to its different forms. Nevertheless,
myopathies associated with mutations in NEB have been
reported to show selective involvement of the anterior leg
compartment muscles, in particular the tibialis anterior,
albeit with variable signal intensity, reflecting the clinical
severity. Among these cases, the severest clinical pheno-
type also includes involvement of the rectus femoris, vas-
tus lateralis and gracilis muscles. Myopathies associated
with mutations in ACTA1 are instead characterized by
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widespread involvement of the muscles of both the thigh
and the lower leg, with the exception of the finding of
greater involvement of the sartorius compared with the
gracilis, and of the soleus compared with the gastrocne-
mius muscles; once again, the anterior leg compartment
muscles (tibialis anterior, peroneal group) are more af-
fected, but in this case involvement of the tibialis posterior
can also be noted [54]. The anterior leg compartment
muscles are also primarily involved in myopathies related
to mutations in MYH7, in which the tibialis anterior is the
first muscle involved and also the one most affected. This
is followed by involvement of the peroneal, soleus and
tibialis posterior muscles. The gastrocnemius lateralis is
generally spared. The thigh muscles can also be spared,
but when they are involved it is the vastus muscles that
are affected, whereas the rectus femoris, adductor longus,
sartorius and gracilis are always spared. Finally, in patients
with mutations in TMP2 there is evident and widespread
involvement of the lower leg muscles and those of the
posterior thigh compartment.
In patients with myopathy related to mutations in
DNM2, muscle MRI often shows predominant involve-
ment of the distal lower leg muscles with early involve-
ment of the plantar flexors [55]. In the thigh there is
selective involvement of the adductor longus, semimem-
branosus, biceps femoris, rectus femoris and vastus inter-
medius, while the vastus lateralis, vastus medialis,
sartorius, gracilis and part of the semintendinosus are
spared; in the lower leg there is predominant involvement
of the soleus, gastrocnemius medialis and tibialis anterior.
There are fewer myoimaging data available in centro-
nuclear myopathy, probably because these forms are less
common and show greater phenotypic severity. That said,
it has been shown that the thigh muscles can be spared in
forms associated with mutations in BIN1, which instead
present with predominant involvement of the lower leg
muscles, both the gastrocnemius medialis and the anterior
compartment muscles, particularly the tibialis anterior (as
in cases with DNM2 mutations), but also the peroneal
muscles, whereas (unlike what has been described in
DNM2-mutated patients) the soleus is preserved. Con-
versely, the few reported cases with mutations in MTM1
show severe involvement of the anterior thigh compart-
ment muscles and of the adductor magnus, while the ad-
ductor longus, sartorius and gracilis are spared. The lower
leg muscle primarily involved is the soleus, while the
gastrocnemius medialis is often spared.
Table 1 summarizes major patterns observed in con-
genital myopathies. To date, most of the studies con-
ducted have selectively investigated the involvement of the
lower limbs, although some new research avenues have
been explored in myoimaging of congenital myopathies,
e.g. the use of a whole-body MR protocol [56, 57]. More-
over, even though the degree of muscle involvement has,
for years, been assessed using semi-quantitative criteria
[49], in recent times there have been some quantitative
analyses, an approach particularly useful for monitoring
the degree of disease progression over time and correlat-
ing it with the clinical evolution; for the moment, how-
ever, longitudinal studies remain scarce [58].
Genetic determinants and relative genotypes
Genotypes in nemaline myopathy
The genes classically associated with nemaline myopathy
encode sarcomeric thin filament proteins. Mutations in
the NEB gene encoding nebulin [59], inherited in an
autosomal recessive manner, are the most frequent (ac-
counting for over 50%), followed by mutations in ACTA1
(around 20%) encoding alpha-actin 1 [60], which show
an autosomal dominant (90%) or recessive (10%) pattern
of inheritance. Some rare cases have been associated
with mutations in the alpha-tropomyosin-3 gene
(TPM3) [61], the beta-tropomyosin-2 gene (TPM2) [62],



















RYR1 ++ + + + - ++ - + ++
SEPN1 + + + - ++ - ++ ++ +
NEB ++ + ++ ++ +
ACTA1 + + + + ++ - + + +
MYH7 + + + - - - -
TPM2 - - - +
DNM2 - ++ - ++ - - ++ ++
BIN1 - - - - - - - - -
MTM1 ++ ++ ++ ++ - - - ++
++ = severely affected muscles; + = affected muscles; empty box = spared muscles
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and the troponin T1 gene (TNNT1) in the Amish
population [63], and more recently also in the gene
encoding cofilin-2 (CFL2), identified in two related
Arab families [64]. This list is expected to grow given
that, in recent years, the application of NGS tech-
nologies has led to the identification of four new
genes potentially involved in this form, namely
KBTBD13, KLHL40, KLHL41 and LMOD3. In particu-
lar, mutations in KBTBD13 have been associated with
a slowly progressive, childhood-onset form in which
axial hypotonia and exercise intolerance are the pre-
dominant clinical features. Prolonged muscle contrac-
tions have been described in some cases. In this
form, it is possible to observe cores as well as the
classic nemaline bodies on muscle biopsy [65]. The
form associated with mutations in KLHL40 is relatively
frequent and very severe, being characterized by fetal
hypokinesia and marked hypotonia. Joint contractures,
chest deformities, fractures and respiratory failure can be
present at birth. Most patients die in early childhood.
Muscle biopsy reveals numerous nemaline bodies, present
in practically all large muscle fibers [66].
Mutations in KLHL41 have been found in five children
with widely varying clinical manifestations, ranging from
severe forms of fetal akinesia and arthrogryposis, to
milder forms with conservation of gait up to 12 years
[67]. Finally, in 21 patients from 14 families, Yuen and
colleagues recently identified homozygous or compound
heterozygous variants in the LMOD3 gene which en-
codes leiomodin-3, a protein essential for the
organization of thin filaments. Clinically this form is ex-
tremely severe: in the majority of patients, alterations
are already present in utero; these include polyhydram-
nios and absence of fetal movements. The condition
commonly results in premature birth. Patients do not
survive longer than 10 years [68] and most die during
the neonatal period due to dysfunction of muscles with
bulbar innervation.
Genotypes in core myopathy
Central core myopathy is classically associated with mu-
tations, dominant or recessive [69, 70], in RYR1 located
on chromosome 19q13.1, which encodes the muscle rya-
nodine receptor (RYR1), a large protein with a molecular
mass of 563.5 kDa that assembles as an oligotetramer
and is located in the sarcoplasmic reticulum, in contact
with the dihydropyridine receptor (DHPR) and other
sarcoplasmic reticulum proteins. RYR1 has a key role in
calcium release and electromechanical coupling in
muscle [71]. RYR1 shows a complex multimeric
organization: the C-terminus serves as the transmem-
brane domain, but also contains other functional do-
mains such as the binding site of calmodulin; the
hydrophilic N-terminal region protrudes into the cyto-
plasm and constitutes the foot of the calcium channel;
the central portion contains several loops in connection
with the DHPR and other domains involved in the for-
mation of the channel [72].
Mutations in RYR1 have been associated with centro-
nuclear myopathies [73] and CFTD [74], and also linked
to a susceptibility to malignant hyperthermia (MH) [75],
a rare but major complication of anesthesia that mani-
fests itself through a lethal rise in body temperature and
tetanic muscle contractions. The mutations that cause
congenital myopathy remain, in general, distinct from
those responsible for MH susceptibility, which are typic-
ally located in the N-terminal region of the gene; differ-
ent pathogenic mechanisms have been proposed to
explain these very diverse clinical manifestations [76].
Nevertheless, it is thought that patients with congenital my-
opathy due to RYR1mutation may also be at risk of MH.
From a genetic perspective, multiminicore myopathy is
more heterogeneous. Indeed, it can be caused both by
mutations in RYR1 (in its autosomal recessive form) and
by mutations in SEPN1 [77]. This latter gene encodes
selenoprotein N1, another sarcoplasmic reticulum glyco-
protein with a molecular weight of di 70 kDa. The





















RYR1 + - - ++ ++ + -
SEPN1 + ++ + ++ ++ + ++ ++
NEB ++ - ++ - +
ACTA1 + + ++ ++ ++ ++ - - +
MYH7 ++ + + - +
TPM2 + + + + + + + + +
DNM2 +/- ++ ++ - ++ ++ -
BIN1 - - ++ + ++ - - ++ -
MTM1 ++ -
++ = severely affected muscles; + = affected muscles; - = spared muscles
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selenoproteins perform an important antioxidant func-
tion and also have a role in calcium homeostasis. Seleno-
protein N deficiency has been associated with satellite
cell loss resulting in impaired muscle regeneration [78].
Mutations in SEPN1 are also responsible for a congenital
muscular dystrophy characterized by marked spinal ri-
gidity (rigid spine muscular dystrophy, RSMD), and pa-
tients with multiminicore myopathy associated with
selenoprotein N deficiency can present clinical features
that partially overlap with those of RSMD patients, such
as early-onset spinal rigidity and respiratory failure [77].
The literature also reports descriptions of dominant
mutations in MYH7, the gene encoding the beta myosin
heavy chain protein whose mutations have been impli-
cated in cardiac (but also skeletal) muscle disorders. Af-
fected individuals present slowly progressive childhood-
onset muscle weakness; this may be distal or proximal
and can be associated with cardiorespiratory impair-
ment. A family history of sudden death has been re-
ported in one family [38]. It is estimated that in around
50% of core myopathies no genetic basis has yet been
identified [79].
Genotypes in centronuclear myopathy
X-linked myotubular myopathy is associated with muta-
tions in MTM1, which encodes myotubularin, a 603-
amino acid phosphatidylinositol 3-phosphate (PI3P)
phosphatase. Myotubularin is a ubiquitous nuclear pro-
tein involved in the transduction of signals between the
nucleus and cytoplasm, and probably related to cell dif-
ferentiation and cell maturation [80].
Autosomal dominant centronuclear myopathy is clas-
sically associated with mutations in DNM2 which codes
for dynamin 2 [81], a GTPase that is involved in the
mechanisms of endocytosis and transport of organelles
along the network of microtubules, and also plays a key
role in centrosome formation [82]. Variants of this gene
have also been identified in a form of dominant
Charcot-Marie Tooth disease associated with cataracts
[83], while homozygous mutations have recently been
described in a Pakistani family with a lethal form of con-
genital arthrogryposis [84].
The BIN1 gene on chromosome 2q14 is, instead, re-
sponsible for an autosomal recessive form of centronuc-
lear myopathy [85], and has recently also been
associated with an autosomal dominant or sporadic
adult form [86]. BIN1 encodes amphiphysin 2, a protein
that has a key role in the mechanisms of exocytosis and
interacts with dynamin to bring about correct position-
ing of the core inside the muscle fiber and the regular
formation of T tubules [87]. Recessive mutations in
BIN1 were described in a small group of Indian and
Moroccan patients with quite a severe phenotype, gener-
ally present at birth (just one childhood-onset case was
reported), and with a mortality rate of 40%. Its clinical
characteristics included marked muscle atrophy and
concomitant cardiomyopathy in some cases; serum CK
could be raised. No respiratory involvement was re-
ported. The autosomal dominant or sporadic form due
to mutations in DNM2, found in the European popula-
tion, is reported to be far less severe and to have a very
late onset, between 20 and 50 years of age. In these
cases, too, there is no respiratory involvement, but
affected individuals can present ptosis and
ophthalmoparesis.
Mutations in RYR1, known to be associated with core
myopathy, seem to be another common cause of centro-
nuclear myopathy and have been described in cases
exhibiting variable phenotypes, which generally include
a neonatal onset with joint contractures and axial hypo-
tonia [88]. In addition to centrally located nuclei, biop-
sies in these patients can also reveal the cores
characteristically associated with mutations in RYR1.
Less commonly, mutations in TTN, which encodes titin,
a giant sarcomeric protein [89], in SPEG, which encodes
a Z-band protein that shows a strong interaction with
MTM1 and also results in dilated cardiomyopathy [90],
and in MYF6 and CCDC7 have been reported in a few
patients with clinical features reminiscent of centronuc-
lear myopathy [91].
Genotypes in congenital fiber-type disproportion (CFTD)
Mutations in the alpha-tropomyosin-3 gene (TPM3), which
may be inherited in an autosomal dominant or recessive
fashion, are the most common cause of CFTD [92, 93]. In
almost all cases, they cause a mild form of the disease. In-
deed, affected patients retain the ability to walk until adult-
hood. Recessive mutations in RYR1 are the second most
common cause of CFTD (accounting for approximately
20% of cases). The finding of a marked fiber size dispropor-
tion (greater than 30–40%) on muscle biopsy may be sug-
gestive of this form [74]. CFTD can also be caused by other
gene mutations showing an autosomal recessive (SEPN1)
or dominant (ACTA1, TPM2 and MYH7) pattern of
inheritance [37, 94, 95].
Genotypes in the most recently described forms
Recently Schartner and colleagues [96] described a novel
class of congenital myopathy associated with recessive
and dominant mutations in CACNA1S, the pore-
forming subunit of DHPR located on the T-tubule in the
proximity of a Ca2+ release channel (ryanodine receptor;
RYR1) on the sarcoplasmic reticulum. Patients presented
perinatal hypotonia, severe axial and generalized weak-
ness and ophthalmoplegia. Analysis of muscle biopsies
demonstrated a characteristic intermyofibrillar network
(due to sarcoplasmic reticulum dilatation), internal nu-
clei, and areas of myofibrillar disorganization.
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Mutations in STAC3 cause an autosomal-recessive dis-
order found in the Lumbee Native American population,
characterized by clinical features including congenital on-
set of muscle weakness, multiple joint contractures, dys-
morphic facial features, and susceptibility to malignant
hyperthermia. Patient muscle biopsies revealed a non-
specific myopathic pattern. STAC3 protein (SH3 and
cysteine-rich domain 3) is an essential component of the
excitation-contraction coupling apparatus [97, 98].
Recessive mutations in SCN4A, encoding the α-
subunit of the skeletal muscle voltage-gated sodium
channel, were recently associated with a novel form of
congenital myopathy. Affected subjects presented vari-
able clinical features including fetal hypokinesia or asso-
ciation of the myopathy with congenital hypotonia,
significant respiratory and swallowing difficulties, spinal
deformities, and facial weakness with ptosis. Muscle bi-
opsies showed myopathic features including fiber size
variability and the presence of fibrofatty tissue of
varying severity, without specific structural abnormal-
ities [99, 100]. Mutations in SCN4A have previously
been described in hypokalemic or hyperkalemic peri-
odic paralysis, paramyotonia, myotonia congenita, and
myasthenic syndrome. Finally, recessive mutations in
SPTBN4, encoding βIV-spectrin, a non-erythrocytic
member of the β-spectrin family, were reported in a
family associated with congenital myopathy, neur-
opathy, and central deafness [101].
The use of massive parallel sequencing to tackle
heterogeneity in congenital myopathies
Massive next-generation sequencing (NGS) is a tech-
nique involving the parallel sequencing of DNA mole-
cules that are spatially separated in a flow cell. It allows
the sequencing, in a single run, of between hundreds of
millions and billions of base pairs of DNA, depending
on the type of NGS technology being used. NGS can be
used for different applications, such as genomic analysis,
whole exome sequencing (WES) targeting the entire set
of human exons (about 1.5% of the human genome),
transcriptome sequencing and metagenomic applica-
tions. The application of NGS platforms generates an
unprecedented amount of information, and this makes
the management, storage and, above all, analysis of the
data a real challenge [102]. This mass of data is such
that an interconnected system (data analysis pipeline)
with a very high operational capacity is required to allow
its storage, management and processing [103]. The ac-
curacy of NGS platforms derives from the repeated se-
quencing of a given region of interest using a massive
and parallel process in which each sequence contributes
to the depth of “coverage”, and makes it possible to ob-
tain a consensus sequence. Excellent reviews, including
[103], illustrate the pros and cons of this innovative
DNA sequencing approach in clinical settings.
The impact of NGS platforms in the field of basic re-
search has been considerable and suggests that this tech-
nology will prove widely applicable. In recent years,
NGS has been increasingly used for the genetic diagnosis
of diseases that, like the different forms of congenital
myopathy, have heterogeneous clinical phenotypes and
involve multiple genes. Congenital myopathy is indeed
an area in which overlapping skeletal muscle biopsy
findings, the lack of specific clinical presentations, and
genetic heterogeneity can all complicate the molecular
diagnostic process to the point that even expert clini-
cians often struggle to make an accurate diagnosis. For
this reason, the use of massive parallel sequencing is
useful in order to reach, rapidly and inexpensively, a de-
finitive diagnosis. Recent testing of panels of disease
genes using massive NGS approaches has given different
findings. In particular, it has been emphasized that the
diagnosis of congenital myopathy is highly dependent on
interpretation of the muscle histology [104], whose fea-
tures can point to a certain type of congenital myopathy,
but are not necessarily gene specific. More than 20 loci
have been linked to the different forms, including three
exceptionally large genes (TTN, NEB and RYR1), and
this, in itself, is a real challenge for molecular diagnosis.
Oliveira and colleagues developed a new massive parallel
sequencing approach that allowed them to simultan-
eously analyze 20 congenital myopathy-related genes.
Results obtained using this approach led to the identifi-
cation of pathogenic variants in 70% of the patients in
their study — this is a large proportion given the consid-
erable genetic and phenotypic heterogeneity of congeni-
tal myopathy — and thus demonstrate the value of this
approach. Similar approaches by other groups have given
heterogeneous results.
Published data demonstrate that more than 40% of pa-
tients affected by an limb-girdle muscular dystrophy or
congenital myopathy usually obtain a molecular diagno-
sis thanks to the use of NGS strategies [105]. The rate of
diagnosis in patients with a distal myopathy or with an
isolated hyperCKemia is lower. NGS data show that a
large proportion of patients (20–30%) have mutations in
genes typically associated with other forms of inherited
myopathy and not traditionally linked to the observed
phenotype [106]. This finding may be taken as further
proof of a clear and strong clinical overlap between dif-
ferent skeletal muscle disorders, and it broadens the
spectrum of disease presentations associated with many
of the congenital myopathy genes. Moreover, using WES
approach the rate of diagnosis in patients with neuro-
muscular disorders ranges from 16% to 47% [105, 107].
Genome sequencing has not been applied in the diag-
nostic setting so far: its cost and, above all, the
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challenges related to the interpretation of the molecular
findings still preclude its routine diagnostic use [108].
Although the use of NGS strategies represents a mod-
ern approach to “solve the unsolved” [109], caution is
still required in the interpretation of massive data. Most
of the inherited myopathies in childhood are clinically
heterogeneous and show overlapping phenotypes; with a
dramatic technical progress and a cost-effective strategy
at hand, many parents and clinicians now decide for
gene tests as first line diagnostics [110]. However the
“excess of pathogenic variants” does not facilitate sorting
out an ultra-rare genetic noise from disease causative
changes and “synergistic heterozygosity” in the patho-
genesis of the disorder is far to be demonstrated in
neuromuscular disorder. Thus, there is a tremendous
need (now more than ever) for truthful definition of
clinical phenotypes using new Phenomics approaches
[111] as well as new consensus and shared criteria in
muscle biopsy interpretations.
Therapeutic considerations
With the exception of the aggressive, very early-onset
forms, congenital myopathy generally has a benign clin-
ical course and prognosis. There currently exist no de-
finitive treatments for all the forms of congenital
myopathy, and it is therefore necessary to plan appropri-
ate rehabilitation care as well as correct management of
cardiac, respiratory and swallowing problems in order to
preserve patients’ basic functions, counteract complica-
tions and ensure a good quality of life [112, 113].
In principle, it remains important to establish the gen-
etic basis of the disease. The identification of mutations
in certain genes has implications for both prognosis and
prevention. For example, respiratory monitoring is par-
ticularly important in patients with mutations in NEB,
ACTA1 or SEPN1, and cardiac disease prevention in pa-
tients harboring mutations in MYH7 or TPM2 [105].
One feature shared by the different forms of congenital
myopathy is that patients tend to show respiratory muscle
impairment, which may be due either to weakness of the
intercostal muscles or to deformities associated with scoli-
osis. In some cases progressive respiratory failure occurs
even when limb strength is preserved. Nocturnal
hypoventilation seems to be particularly common in
young adult patients and this condition, if untreated, can
cause sudden death. A forced vital capacity corresponding
to 60 % of the predicted value is a useful threshold, below
which studies should be performed to ascertain whether
the patient is affected by nocturnal hypoventilation.
Several case reports and studies on small populations
document the effectiveness of a beta2 agonist (albuterol/
salbutamol) as a means of boosting exercise resistance in
forms of congenital myopathy with early fatigability; as a
secondary effect, this drug also favors bronchodilation
[114]; unfortunately, however, since the respiratory in-
sufficiency in these forms is due to the inability of the
inspiratory muscles to expand the rib cage, salbutamol
has little effect in this regard.
Recent research has offered new opportunities for therap-
ies and new information is now accessible to patients and
physicians (see URL https://clinicaltrials.gov/ct2/results?
cond=Congenital+Myopathy&term = &cntry1 = &state1 =
&recrs=). Specifically, there are there are attempts to
modulate calcium release from the sarcoplasmic reticulum
in central core disease due to mutations in RYR1 (using
dantrolene, 5-aminoimidazole-4-carboximide ribonucleo-
side, and 1,4-benzothiazepine derivatives JTV519 and S107)
and also to correct the abnormalities of oxidative metabol-
ism (with N-acetylcysteine) [112]. In XLMTM, there are
new opportunities by applying in a clinical setting AAV8-
based gene therapy already known to improve the clinical
and histopathological phenotype in Mtm1-knock-out mice,
and to increase muscle strength and survival in a canine
model [112]. Most orthopedic abnormalities in congenital
myopathy are quite amenable to conservative or surgical
treatment. In patients with severe scoliosis, an early surgical
approach may be recommended in order to better preserve
respiratory function. Achilles tendon contractures can de-
velop in patients with distal involvement and can some-
times necessitate surgical lengthening of the tendon.
Physical therapy to maintain proper joint function
is often useful. Possible options, in the most severe
cases, are insoles or braces to stabilize gait and main-
tain the upright position for as long as possible. It
has, in fact, been shown that conserving gait and the
upright position can delay the onset of spinal
deformity.
Although evidence that patients with congenital my-
opathy benefit from specific physiotherapy exercise
regimens is scarce [115], it is known that regular aer-
obic exercise, such as cycling, hydrotherapy and,
when possible, swimming, is advantageous. These pa-
tients may have an increased risk of osteoporosis and
bone fractures. Calcium supplementation and the
maintenance of adequate levels of vitamin D are
therefore recommended. Bone mineral density assess-
ments may identify patients at increased risk of osteo-
penia. Cardiomyopathy is rarely associated with
congenital myopathy, but it is a potential issue in the
presence of mutations in certain genes such as TTN
and MYH7. It may therefore be advisable to perform
a cardiac examination with echocardiogram or elec-
trocardiogram every 2–3 years in childhood, and
every 3–5 in adulthood, or more frequently if clinical
manifestations appear. The potential use, in some
forms, of antioxidant therapy, such as ubidecarenone,
to prevent cardiac or respiratory muscle dysfunction
is debated [116].
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Conclusions
In this manuscript, we reviewed clinical and genetic
forms of congenital myopathies and defined possible
histological and imaging characteristics that can im-
prove cost-effectiveness in diagnosis if carefully bal-
anced in the clinical setting. While detecting
congenital myopathy appear to be easy, establishing
its correct genetic diagnosis is not. Indeed, there is
no direct link between specific, histologically defined
forms of congenital myopathy and their genetic cause,
as many of the histological patterns can actually be
caused by mutations in different genes, while muta-
tions in a single gene can result in various histo-
pathological abnormalities (Table 2). Thus, it is
important to classify patients correctly and the sug-
gested use of two broad categories based on age at
onset: neonatal and infancy onset and later childhood
onset appear to provide a first guide in prioritizing
genetic testing in affected patients [1]. To date, appli-
cations of NGS methodologies (especially targeted
gene panels of multiple genes) seem to be the best
approach to adopt in the years to come in the diag-
nosis of congenital myopathy, as it allows lower costs
and shorter times of analysis compared with trad-
itional Sanger sequencing, especially considering the
large size of genes such as NEB, TTN and RYR1. As
in many NGS studies, the real challenge, however,
will be to succeed in distinguishing true pathogenic
mutations from population polymorphisms, and to
achieve functional validation of possible new genes/
mutations. It is also necessary to appreciate that sin-
gle patients may be found to carry different mutations
in multiple genes, and that some of these may play a
role in the expression of the phenotype (gene modu-
lators). The clinical use of NGS multigene testing,
however, should be reserved to a step when clinical
data and imaging or histological evidences in muscle
have already been collected and carefully classified.
Genotype without deep phenotype, indeed, might
prove useless and hinder pinpointing the true gene
rather than accelerate the “diagnostic odyssey”. Too
rapid genotyping may produce several false positive
or increase the number of genetic variants whose
pathogenic significance needs to be functionally
corroborated.
Identification of the true gene mutation [41] is the
prerequisite for more precise clinical stratification. Al-
though curative opportunities are scarce, emerging evi-
dences of new therapeutic strategies, including gene
transfer in X-linked myotubular myopathy, enzyme re-
placement in MTMR14-related congenital myopathies,
anti-atrophy approaches, in addition to upregulation of
the fetal isoform of skeletal muscle a-actin in patients
with recessive mutations in ACTA1 [66, 117] open new
chances and challenges. The significant overlap between
genetic and structural subgroups of the congenital my-
opathies suggest that possible therapies may be operative
in a broad range of conditions and perhaps also benefit a
range of patients beyond the limits of their clinical syn-
dromes [118]. Overall, this demands for an even more
accurate stratification of patients and collection of
meaningful outcome measures for future trials.
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